600267 海正药业
已收盘 04-17 15:00:00
资讯
新帖
简况
海正药业最新公告:2026年一季度净利润同比增长83.13%
证券之星 · 04-15 17:01
海正药业最新公告:2026年一季度净利润同比增长83.13%
海正药业发布2026年第一季度业绩快报,盈利3.557亿元
证券之星 · 04-15 17:00
海正药业发布2026年第一季度业绩快报,盈利3.557亿元
4月15日海正药业涨10.05%,浙商汇金量化精选混合A基金重仓该股
证券之星 · 04-15 16:12
4月15日海正药业涨10.05%,浙商汇金量化精选混合A基金重仓该股
国办一纸文件定调药价,创新药爆发!涨停名单还在拉长
格隆汇 · 04-15 14:33
国办一纸文件定调药价,创新药爆发!涨停名单还在拉长
每周股票复盘:海正药业(600267)股东户数降6.51%
证券之星 · 04-12
每周股票复盘:海正药业(600267)股东户数降6.51%
海正药业(600267)2025年年报简析:增收不增利
证券之星 · 04-09
海正药业(600267)2025年年报简析:增收不增利
海正药业(600267.SH)发布2025年度业绩,归母净利润5.41亿元,同比下降10.06%
智通财经 · 04-07
海正药业(600267.SH)发布2025年度业绩,归母净利润5.41亿元,同比下降10.06%
每周股票复盘:海正药业(600267)拟回购注销87000股限制性股票
证券之星 · 04-05
每周股票复盘:海正药业(600267)拟回购注销87000股限制性股票
海正药业(600267)披露股权激励限制性股票回购注销实施公告,4月2日股价下跌0.28%
证券之星 · 04-02
海正药业(600267)披露股权激励限制性股票回购注销实施公告,4月2日股价下跌0.28%
每周股票复盘:海正药业(600267)注射用盐酸伊达比星通过一致性评价
证券之星 · 03-29
每周股票复盘:海正药业(600267)注射用盐酸伊达比星通过一致性评价
海正药业(600267)披露公司药品通过仿制药一致性评价的公告,3月26日股价上涨0.3%
证券之星 · 03-26
海正药业(600267)披露公司药品通过仿制药一致性评价的公告,3月26日股价上涨0.3%
海正药业最新公告:子公司注射用盐酸伊达比星(5mg)通过仿制药一致性评价
证券之星 · 03-26
海正药业最新公告:子公司注射用盐酸伊达比星(5mg)通过仿制药一致性评价
股市必读:海正药业(600267)3月23日收盘跌7.86%,主力净流出824.55万元
证券之星 · 03-24
股市必读:海正药业(600267)3月23日收盘跌7.86%,主力净流出824.55万元
每周股票复盘:海正药业(600267)完成近亿元股份回购
证券之星 · 03-22
每周股票复盘:海正药业(600267)完成近亿元股份回购
海正药业公布国际专利申请:“取代双环类衍生物及其制备方法和用途”
证券之星 · 03-21
海正药业公布国际专利申请:“取代双环类衍生物及其制备方法和用途”
海正药业(600267)披露第四次股份回购实施结果暨股份变动公告,3月17日股价下跌0.38%
证券之星 · 03-17
海正药业(600267)披露第四次股份回购实施结果暨股份变动公告,3月17日股价下跌0.38%
海正药业最新公告:全资子公司瀚晖制药获得海博麦布阿托伐他汀钙片临床试验批准通知书
证券之星 · 03-16
海正药业最新公告:全资子公司瀚晖制药获得海博麦布阿托伐他汀钙片临床试验批准通知书
每周股票复盘:海正药业(600267)股东拟转让6.06%股份
证券之星 · 03-15
每周股票复盘:海正药业(600267)股东拟转让6.06%股份
海正药业(600267)披露持股5%以上股东拟协议转让股份更正公告,3月10日股价上涨1.16%
证券之星 · 03-10
海正药业(600267)披露持股5%以上股东拟协议转让股份更正公告,3月10日股价上涨1.16%
每周股票复盘:海正药业(600267)子公司获兽药批件
证券之星 · 03-08
每周股票复盘:海正药业(600267)子公司获兽药批件
暂无数据
公司概况
公司名称:
浙江海正药业股份有限公司
所属行业:
医药制造业
上市日期:
2000-07-25
主营业务:
浙江海正药业股份有限公司的主营业务是化学原料药和制剂的研发、生产和销售业务。公司的主要产品是抗肿瘤药、抗感染药、心血管药、抗寄生虫药及兽药、内分泌药、其他药品、医药商业、CMO/CDMO/CRO业务、其他。公司入选中国医药工业信息中心“2025年中国医药研发产品线工业企业优秀案例”、2024年度中国医药工业百强榜、人民网“2025人民企业社会责任案例”;获得第90届药交会“首届创新药上市解决方案大赛”综合实力奖,入选2025中国制药工业TOP101榜单;荣膺EcoVadis铜牌认证,可持续发展实践获国际认可;子公司瀚晖制药荣获“浙江省先进级智能工厂”认定;澐生合成荣获BRCGSA级认证,打造合成生物学质量新标杆。
发行价格:
11.83
{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"海正药业","latestPrice":11.24,"timestamp":1776409200000,"preClose":11.53,"halted":0,"volume":61553832,"delay":0,"changeRate":-0.0252,"floatShares":1199000000,"shares":1199000000,"eps":0.4007,"marketStatus":"已收盘","change":-0.29,"latestTime":"04-17 15:00:00","open":11.47,"high":11.63,"low":11.11,"amount":692000000,"amplitude":0.0451,"askPrice":11.25,"askSize":725,"bidPrice":11.24,"bidSize":904,"shortable":0,"etf":0,"ttmEps":0.4007,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":11.53,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":12.68,"lowLimit":10.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1198761196,"isCdr":false,"pbRate":1.57,"roa":"--","peRate":28.050911,"roe":"6.41%","epsLYR":0.46,"committee":-0.42034,"marketValue":13474000000,"turnoverRate":0.0513,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-04-20。","floatMarketCap":13474000000},"requestUrl":"/m/hq/s/600267/tweets","defaultTab":"tweets","newsList":[{"id":"2627407360","title":"海正药业最新公告:2026年一季度净利润同比增长83.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407360","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407360?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:01","pubTimestamp":1776243704,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称,公司2026年第一季度实现营业收入23.90亿元,同比下降9.17%;归属于上市公司股东的净利润为3.56亿元,同比增长83.13%。业绩变动主要系转让子公司股权致非经常性损益增加,以及医药制剂销售增长、生产降本增效等因素影响。注:公司Q1净利润3.56亿,2025年Q4净利润0.8亿,据此计算,Q1净利润环比增长345%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407312","title":"海正药业发布2026年第一季度业绩快报,盈利3.557亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407312","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407312?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:00","pubTimestamp":1776243656,"startTime":"0","endTime":"0","summary":"证券之星消息,海正药业近日即将发布2026年一季报,根据4月15日发布的业绩快报,归属净利润盈利3.557亿元,同比增长83.13%。业绩快报公告中对经营业绩和财务状况情况的说明:2026 年第一季度,公司围绕年度经营计划稳步开展各项工作,持续优化业务结构,强化生产管理与协同运营,经营业绩稳步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","600267","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627040474","title":"4月15日海正药业涨10.05%,浙商汇金量化精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627040474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627040474?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:12","pubTimestamp":1776240745,"startTime":"0","endTime":"0","summary":"证券之星消息,4月15日海正药业涨10.05%创60日新高,收盘报11.39元,换手率4.12%,成交量49.33万手,成交额5.48亿元。重仓海正药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为浙商证券资管的浙商汇金量化精选混合A。该公募基金现任基金经理为陈顾君。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价,创新药爆发!涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"sh","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159992","000919","BK0097","BK0070","BK0077","002038","002589","BK0028","301408","06978","BK0209","BK1583","BK0012","BK0122","000788","BK1574","BK0185","BK0096","BK0132","LU0196878994.USD","BK0102","BK0060","BK1161","BK1587","06990","02162","BK0197","BK0188","600572","600267","600488","BK0239","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626640122","title":"每周股票复盘:海正药业(600267)股东户数降6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626640122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626640122?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:56","pubTimestamp":1775930169,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘,海正药业报收于10.27元,较上周的10.53元下跌2.47%。本周,海正药业4月7日盘中最高价报10.74元。股本股东变化截至2026年3月31日,海正药业股东户数为4.77万户,较2025年12月31日减少3319户,减幅6.51%。业绩披露要点海正药业2025年实现主营收入105.5亿元,同比增长2.02%;归母净利润5.41亿元,同比下降10.06%;扣非净利润5.86亿元,同比增长36.11%。本次注销股份占总股本1.54%,不影响公司持续经营能力及上市条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626978381","title":"海正药业(600267)2025年年报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2626978381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626978381?lang=zh_cn&edition=full","pubTime":"2026-04-09 06:02","pubTimestamp":1775685735,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期海正药业发布2025年年报。根据财报显示,海正药业增收不增利。截至本报告期末,公司营业总收入105.5亿元,同比上升2.02%,归母净利润5.41亿元,同比下降10.06%。按单季度数据看,第四季度营业总收入26.27亿元,同比上升6.54%,第四季度归母净利润7977.86万元,同比下降7.09%。该数据低于大多数分析师的预期,此前分析师普遍预期2025年净利润为盈利7.07亿元左右。本次财报公布的各项数据指标表现一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900003186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","600267","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625593077","title":"海正药业(600267.SH)发布2025年度业绩,归母净利润5.41亿元,同比下降10.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625593077","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625593077?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:13","pubTimestamp":1775564031,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)披露2025年年度报告,报告期公司实现营收105.5亿元,同比增长2.03%;归属于上市公司股东的净利润5.41亿元,同比下降10.06%;扣非净利润5.86亿元,同比增长36.11%;基本每股收益0.46元。公司拟向全体股东每股派发现金0.21元(含税)。2025年度归属于上市公司股东的扣除非经常性损益的净利润较上年同期增长36.11%,主要系公司持续推进制剂产品市场推广工作,产品销量实现稳步增长;营销体系持续优化升级,运营管理效率稳步提升;同时通过深化生产精细化管理,有效落实降本增效措施,推动公司整体盈利水平持续改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616139","title":"每周股票复盘:海正药业(600267)拟回购注销87000股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616139?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:12","pubTimestamp":1775326333,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,海正药业报收于10.53元,较上周的10.24元上涨2.83%。本周,海正药业4月2日盘中最高价报10.84元。本次回购注销已于2026年2月5日经公司第十届董事会第十三次会议审议通过,并已完成债权人通知程序。注销日期为2026年4月7日,注销后公司有限售条件的流通股减少至0股,总股本相应减少。本次回购注销不会对公司财务状况和经营成果产生实质性影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0028","600267","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624350744","title":"海正药业(600267)披露股权激励限制性股票回购注销实施公告,4月2日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624350744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624350744?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:30","pubTimestamp":1775140235,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘,海正药业报收于10.74元,较前一交易日下跌0.28%,最新总市值为128.76亿元。浙江海正药业股份有限公司于近日发布《关于股权激励限制性股票回购注销实施公告》。本次回购注销已于2026年2月5日经公司第十届董事会第十三次会议审议通过,并已完成债权人通知程序。注销日期为2026年4月7日,注销后公司有限售条件的流通股减少至0股,总股本相应减少。相关决策程序和信息披露符合法律法规及激励计划规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","600267","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623380511","title":"每周股票复盘:海正药业(600267)注射用盐酸伊达比星通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2623380511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623380511?lang=zh_cn&edition=full","pubTime":"2026-03-29 02:06","pubTimestamp":1774721173,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,海正药业报收于10.24元,较上周的10.31元下跌0.68%。本周关注点公司公告汇总:注射用盐酸伊达比星通过仿制药一致性评价,有利于提升市场竞争力。公司公告汇总浙江海正药业股份有限公司全资子公司瀚晖制药有限公司收到国家药监局核准签发的注射用盐酸伊达比星《药品补充申请批准通知书》,该药品已通过仿制药质量和疗效一致性评价。注射用盐酸伊达比星适用于成人急性非淋巴细胞性白血病和急性淋巴细胞性白血病的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600267","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622555869","title":"海正药业(600267)披露公司药品通过仿制药一致性评价的公告,3月26日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622555869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622555869?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:32","pubTimestamp":1774535566,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,海正药业报收于9.87元,较前一交易日上涨0.3%,最新总市值为118.33亿元。该股当日开盘9.85元,最高10.05元,最低9.81元,成交额达8764.17万元,换手率为0.74%。近日,浙江海正药业股份有限公司全资子公司瀚晖制药有限公司收到国家药监局核准签发的注射用盐酸伊达比星《药品补充申请批准通知书》,该药品已通过仿制药质量和疗效一致性评价。公司该产品2025年销售额约为3,604万元人民币。截至目前,公司为此投入约1,790万元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0239","BK0028","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622255858","title":"海正药业最新公告:子公司注射用盐酸伊达比星(5mg)通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2622255858","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622255858?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:17","pubTimestamp":1774516658,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称,公司全资子公司瀚晖制药收到国家药监局核准签发的《药品补充申请批准通知书》,其药品注射用盐酸伊达比星(5mg)已通过仿制药质量和疗效一致性评价。注射用盐酸伊达比星适用于成人未经治疗的急性非淋巴细胞性白血病(ANLL)的诱导缓解和成人复发和难治性ANLL的诱导缓解,以及用于成人和儿童急性淋巴细胞性白血病(ALL)的二线治疗,原研是辉瑞公司。截至公告日,公司针对该规格一致性评价已投入约1,790万元。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600031028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600267","BK0188","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621086167","title":"股市必读:海正药业(600267)3月23日收盘跌7.86%,主力净流出824.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621086167","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621086167?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:48","pubTimestamp":1774291693,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,海正药业报收于9.5元,下跌7.86%,换手率2.09%,成交量25.1万手,成交额2.46亿元。来自资金流向:3月23日主力资金净流出824.55万元,而游资资金净流入2632.64万元。交易信息汇总股价提醒3月23日海正药业收盘报9.5元,跌7.86%,当日成交2510.47万元。根据收盘数据统计,该股已连续5日下跌。前10个交易日资金流向情况:主力资金累计净流出6234万元,股价累计下跌8.01%;融资余额累计减少3449.66万元,融券余量累计增加12.83万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621791624","title":"每周股票复盘:海正药业(600267)完成近亿元股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2621791624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621791624?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:39","pubTimestamp":1774121950,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,海正药业报收于10.31元,较上周的10.55元下跌2.27%。本周,海正药业3月17日盘中最高价报10.73元。本周关注点公司公告汇总:海正药业全资子公司获药物临床试验批准通知书。浙江海正药业股份有限公司关于第四次股份回购实施结果暨股份变动公告浙江海正药业股份有限公司于2025年5月12日召开董事会,审议通过第四次以集中竞价交易方式回购股份的议案,并于2025年5月13日披露回购方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","600267","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621752701","title":"海正药业公布国际专利申请:“取代双环类衍生物及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752701","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621752701?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:54","pubTimestamp":1774043676,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示海正药业(600267)公布了一项国际专利申请,专利名为“取代双环类衍生物及其制备方法和用途”,专利申请号为PCT/CN2025/120367,国际公布日为2026年3月19日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来海正药业已公布的国际专利申请7个,较去年同期增加了600%。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了2.02亿元,同比增13.98%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032100004177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600267","BK0028","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620473792","title":"海正药业(600267)披露第四次股份回购实施结果暨股份变动公告,3月17日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620473792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620473792?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:25","pubTimestamp":1773757517,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘,海正药业报收于10.58元,较前一交易日下跌0.38%,最新总市值为126.84亿元。近日,浙江海正药业股份有限公司发布《关于第四次股份回购实施结果暨股份变动公告》。公告显示,公司于2025年5月12日召开董事会,审议通过第四次以集中竞价交易方式回购股份的议案,并于2025年5月13日披露回购方案。本次回购股份拟用于员工持股计划,不会影响公司正常经营和股权分布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","600267","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619451258","title":"海正药业最新公告:全资子公司瀚晖制药获得海博麦布阿托伐他汀钙片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619451258","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619451258?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:19","pubTimestamp":1773656391,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称,公司全资子公司瀚晖制药收到国家药监局核准签发的海博麦布阿托伐他汀钙片的《药物临床试验批准通知书》。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600028178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0239","BK0028","BK0060","BK1574","600267","BK0188","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619120404","title":"每周股票复盘:海正药业(600267)股东拟转让6.06%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619120404","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619120404?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:25","pubTimestamp":1773512714,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,海正药业报收于10.55元,较上周的10.37元上涨1.74%。本周,海正药业3月13日盘中最高价报10.6元。3月9日盘中最低价报10.27元。海正药业当前最新总市值126.48亿元,在化学制药板块市值排名41/150,在两市A股市值排名1657/5190。本周关注点公司公告汇总:持股5%以上股东拟通过公开征集转让方式协议转让公司6.06%股份。主要更正内容为意向受让方资格条件中的基本条件,将“境内法人”更正为“境内企业”,其余内容不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0060","600267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618959735","title":"海正药业(600267)披露持股5%以上股东拟协议转让股份更正公告,3月10日股价上涨1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618959735","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618959735?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:28","pubTimestamp":1773152897,"startTime":"0","endTime":"0","summary":"截至2026年3月10日收盘,海正药业报收于10.45元,较前一交易日上涨1.16%,最新总市值为125.28亿元。近日,浙江海正药业股份有限公司发布《关于持股5%以上股东拟通过公开征集转让方式协议转让公司股份的更正公告》。公告显示,持股5%以上股东浙江省国际贸易集团有限公司拟通过公开征集转让方式协议转让公司6.06%股份;本次更正主要涉及意向受让方资格条件中的基本条件,将原表述“境内法人”更正为“境内企业”,其余内容不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000038489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0060","BK0239","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668028","title":"每周股票复盘:海正药业(600267)子公司获兽药批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668028","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668028?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:45","pubTimestamp":1772909114,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,海正药业报收于10.37元,较上周的10.42元下跌0.48%。本周关注点公司公告汇总:子公司获盐酸特比萘芬片兽药产品批准文号,可用于犬皮肤感染治疗。浙江海正药业股份有限公司于2025年8月22日召开董事会,审议通过转让全资子公司浙江省医药工业有限公司100%股权的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600267","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776451830359,"stockEarnings":[{"period":"1week","weight":0.0944},{"period":"1month","weight":0.0674},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.0913},{"period":"1year","weight":0.2784},{"period":"ytd","weight":0.1365}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.0123},{"period":"6month","weight":0.0551},{"period":"1year","weight":0.2351},{"period":"ytd","weight":0.0208}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47673人(较上一季度减少6.51%)","perCapita":"25145股","listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","registeredCapital":"119876万元","survey":" 浙江海正药业股份有限公司的主营业务是化学原料药和制剂的研发、生产和销售业务。公司的主要产品是抗肿瘤药、抗感染药、心血管药、抗寄生虫药及兽药、内分泌药、其他药品、医药商业、CMO/CDMO/CRO业务、其他。公司入选中国医药工业信息中心“2025年中国医药研发产品线工业企业优秀案例”、2024年度中国医药工业百强榜、人民网“2025人民企业社会责任案例”;获得第90届药交会“首届创新药上市解决方案大赛”综合实力奖,入选2025中国制药工业TOP101榜单;荣膺EcoVadis铜牌认证,可持续发展实践获国际认可;子公司瀚晖制药荣获“浙江省先进级智能工厂”认定;澐生合成荣获BRCGSA级认证,打造合成生物学质量新标杆。","listedPrice":11.83},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海正药业,600267,海正药业股票,海正药业股票老虎,海正药业股票老虎国际,海正药业行情,海正药业股票行情,海正药业股价,海正药业股市,海正药业股票价格,海正药业股票交易,海正药业股票购买,海正药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}